Retinol‐binding protein 4 (RBP4), a potential biomarker of frailty in HIV‐infected people on stable antiretroviral therapy.

Objectives: A quantitative biomarker for identification of pre‐frail and frail persons is still lacking. This study aimed to identify biomarker predictors of frailty in HIV‐infected patients. Methods: A cross‐sectional study of HIV‐infected patients who had been on antiretroviral therapy (ART) for at least 1 year and who presented an undetectable viral load (< 50 HIV‐1 RNA copies/mL) at baseline was carried out. For each frail patient, up to four pre‐frail and robust patients were randomly selected. The frailty status assessment was based on the five‐item criteria described by Fried et al. Sociodemographic, anthropometric, biochemical and HIV‐related characteristics were evaluated. Multiple potential biomarkers of frailty and a biological age biomarker were analysed. Results: A total of 73 HIV‐infected patients on ART for at least 1 year were evaluated. The patients were categorized as robust (n = 33), pre‐frail (n = 32) and frail (n = 8) using the Fried criteria. All patients were on ART, with 100% undetectable viral load (< 50 copies/mL) at baseline. No significant differences in demographic, clinical or analytical characteristics were observed among patients in the different categories based on Fried criteria, with the exception of the veterans aging cohort study index (VACS). Similarly, no differences were observed in HIV‐related characteristics, although nucleoside reverse transcriptase inhibitor (NRTI) use was less common in frail persons. The distribution of biomarker values varied according to frailty status, with frail persons having higher levels of interleukin (IL)‐8, IL‐18, CXC chemokine ligand 10 (CXCL10) and retinol‐binding protein 4 (RBP4). In multivariable analysis, the assocation of frailty with RBP4 showed a tendency to statistical significance (odds ratio 1.0; 95% confidence interval 0.99–1.00; P < 0.05). Conclusions: Differential biomarker expression was present according to Fried status. Longitudinal studies will clarify the utility of these biomarkers as targets for diagnostic or therapeutic intervention. [ABSTRACT FROM AUTHOR]